Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Jan;60(570):e20-7.
doi: 10.3399/bjgp09X482312.

Cost-effectiveness of shared pharmaceutical care for older patients: RESPECT trial findings

RESPECT Trial Team
Collaborators
Randomized Controlled Trial

Cost-effectiveness of shared pharmaceutical care for older patients: RESPECT trial findings

RESPECT Trial Team. Br J Gen Pract. 2010 Jan.

Abstract

Background: Pharmaceutical care serves as a collaborative model for medication review. Its use is advocated for older patients, although its cost-effectiveness is unknown. Although the accompanying article on clinical effectiveness from the RESPECT (Randomised Evaluation of Shared Prescribing for Elderly people in the Community over Time) trial finds no statistically significant impact on prescribing for older patients undergoing pharmaceutical care, economic evaluations are based on an estimation, rather than hypothesis testing.

Aim: To evaluate the cost-effectiveness of pharmaceutical care for older people compared with usual care, according to National Institute for Health and Clinical Excellence (NICE) reference case standards.

Methods: An economic evaluation was undertaken in which NICE reference case standards were applied to data collected in the RESPECT trial.

Results: On average, pharmaceutical care is estimated to cost an incremental 10 000 UK pounds per additional quality-adjusted life year (QALY). If the NHS's cost-effectiveness threshold is between 20 000 and 30 000 UK pounds per extra QALY, then the results indicate that pharmaceutical care is cost-effective despite a lack of statistical significance to this effect. However, the statistical uncertainty surrounding the estimates implies that the probability that pharmaceutical care is not cost-effective lies between 0.22 and 0.19. Although results are not sensitive to assumptions about costs, they differ between subgroups: in patients aged >75 years pharmaceutical care appears more cost-effective for those who are younger or on fewer repeat medications.

Conclusion: Although pharmaceutical care is estimated to be cost-effective in the UK, the results are uncertain and further research into its long-term benefits may be worthwhile.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Monte Carlo simulation of costs and QALYs and cost-effectiveness acceptability curve.
Figure 2
Figure 2
Modelled expected utility over time for average patient type.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. RESPECT trial team. Effectiveness of shared pharmaceutical care for older patients: RESPECT trial findings. Br J Gen Pract. 2009 DOI: 10.3399/bjgp09X473295. - PMC - PubMed
    1. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2004. - PubMed
    1. Rabin R, Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337–343. - PubMed
    1. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2008. - PubMed
    1. Curtis L, Netton A. Unit costs of health and social care. Canterbury: Personal Social Services Research Unit, University of Kent; 2005.

Publication types

MeSH terms

Substances

LinkOut - more resources